Pharmaceutical care on a patient with bronchiectasis, diabetes and gout

CAO Qin; LI Yuliu

doi:10.3969/j.issn.1006-0111.2017.02.019

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To explore the breakthrough point of pharmaceutical care for a patient with bronchiectasis, diabetes and gout. Methods The clinical pharmacist recommended appropriate antibiotics and gout medications. The dosage and therapy regimen were optimized based on the patient's renal function, allergy and disease history. Results The physician accepted the suggestions from clinical pharmacists. The patient recovered well with no adverse drug reactions. Conclusion With the knowledge of clinical pharmacist, clinical treatment plan was optimized. The patient received better pharmaceutical care.

Pharmaceutical care on a patient with bronchiectasis, diabetes and gout

Department of Pharmacy, 8690 of Chinese People's Armed Police Forces Hospital, Yixing 214205, China

Received Date: 2016-10-18

Rev Recd Date: 2016-12-30

Key words:

Abstract: Objective To explore the breakthrough point of pharmaceutical care for a patient with bronchiectasis, diabetes and gout. Methods The clinical pharmacist recommended appropriate antibiotics and gout medications. The dosage and therapy regimen were optimized based on the patient's renal function, allergy and disease history. Results The physician accepted the suggestions from clinical pharmacists. The patient recovered well with no adverse drug reactions. Conclusion With the knowledge of clinical pharmacist, clinical treatment plan was optimized. The patient received better pharmaceutical care.

HTML

Reference (8)

[1]	成人支气管扩张症诊治专家共识编写组.成人支气管扩张症诊治专家共识[J].中华结核和呼吸杂志, 2012,35(7):485-492.
[2]	李詝,李久荣,高金明.北京协和医院136例支气管扩张症住院患者临床特征分析[J].中国医学科学院学报,2014,36(1):61-67.
[3]	Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE):a randomized, double-blind, placebo-controlled trial[J].Lancet,2012,380(9842):660-667.
[4]	Altenburg J, de Graaf CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis:The BAT Randomized Controlled Trail[J]. JAMA,2013,309(12):1251-1259.
[5]	Anwar GA, Bourke SC, Afolabi G,et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis[J]. Respir Med, 2008,102(10):1494-1496.
[6]	Li H, Liu DH, Chen LL, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases[J].Antimicrob Agents Chemother,2014,58(1):511-517.
[7]	Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, et al. Azithromycin:Mechanisms of action and their relevance for clinical applications[J]. Pharmacol Ther, 2014,143(2):225-245.
[8]	周启蒙,杜冠华.治疗高尿酸血症相关药物研究进展[J].中国新药杂志,2016,25(18):2129-2135.

Message Board

Pharmaceutical care on a patient with bronchiectasis, diabetes and gout

doi: 10.3969/j.issn.1006-0111.2017.02.019

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views